News
Steep cost of surviving childhood HL: Epigenetic aging
- Author:
- Neil Osterweil
New research found accelerated epigenetic aging in most adults who survived pediatric Hodgkin lymphoma.
News
Alloantibody registry would save lives, money
- Author:
- Neil Osterweil
New research supports establishing a national exchange of alloantibody data, to save lives and cut costs in transfusion medicine.
News
Gene signature may spare some breast cancer patients from radiation
- Author:
- Neil Osterweil
The POLAR 16-gene mRNA signature accurately identified patients who were unlikely to benefit from radiotherapy after breast-conserving surgery.
News
‘Exciting’ responsiveness to talquetamab for r/r MM
- Author:
- Neil Osterweil
The novel antibody talquetamab may buy time for patients with multiple myeloma (MM) for whom few other options remain.
News
Pricey gene therapy looks cost-effective for SCD
- Author:
- Neil Osterweil
Researchers calculated that a costly new treatment being developed for sickle cell disease (SCD) promises to be worth the price.
News
A bold national plan to eliminate HCV by 2050
- Author:
- Neil Osterweil
“We don’t get to use the ‘eliminate’ word all that often with a disease that’s taking thousands or tens of thousands – or worldwide, hundreds of...
News
High response rates with T-DXd in early HER2-low breast cancer
- Author:
- Neil Osterweil
Nearly 70% of patients with hormone receptor-positive breast cancers with low levels of HER2 had pathological response to the antibody-drug...
News
‘Clear answer’: ALL study defies conventional wisdom
- Author:
- Neil Osterweil
Research on pediatric blood cancers found that high-dose methotrexate does not help cut the risk for central nervous system relapse.
News
‘Astonishing’ results: Skip salvage chemo, proceed to HSCT
- Author:
- Neil Osterweil
New research on treating acute myeloid leukemia suggested that some patients may safely go straight to stem cell transplantation.
News
Oral SERD camizestrant prolongs PFS vs. fulvestrant in breast cancer
- Author:
- Neil Osterweil
The investigational selective estrogen receptor degrader showed efficacy in advanced ER+/HER2– breast cancers, including patients with ESR1...
News
Chemotherapy meets its match against aggressive ER+/HER2– breast cancers
- Author:
- Neil Osterweil
Ribociclib plus endocrine therapy resulted in high response rates and double progression-free survival over combo chemotherapy.
News
Potential cause of worse outcomes among Black breast cancer patients found
- Author:
- Neil Osterweil
Tumor microenvironment of metastasis doorways predicted worse outcomes in Black women with residual ER+/HER2– cancer after neoadjuvant...
News
ASH 2022: New clinical data challenge long-held assumptions
- Author:
- Neil Osterweil
Fresh research to be unveiled at the 2022 American Society of Hematology conference seems to overturn conventional wisdom across a range of issues...
News
Poor NAFLD outcomes with increased VCTE-measured liver stiffness
- Author:
- Neil Osterweil
The findings show that “progression to LSM-defined cirrhosis by VCTE is strongly associated with poor clinical outcomes.”
News
New ACR vaccination guideline: Take your best shot
- Author:
- Neil Osterweil
Vaccinate patients with rheumatic and musculoskeletal disease against flu and other vaccine-preventable disease whenever possible, experts say.